(-0.15%) 5 461.37 points
(-0.33%) 38 983 points
(0.21%) 17 755 points
(-0.04%) $80.80
(-3.48%) $2.66
(-0.99%) $2 307.70
(-0.46%) $28.74
(1.26%) $998.80
(0.25%) $0.936
(0.87%) $10.70
(0.36%) $0.791
(-0.27%) $87.25
Live Chart Being Loaded With Signals
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally...
Stats | |
---|---|
本日の出来高 | 24.21M |
平均出来高 | 5.97M |
時価総額 | 0.00 |
EPS | $-0.390 ( Q3 | 2022-11-09 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.0390 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0770 (94.83%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-11-01 | Gross Paul Edward | Buy | 4 625 | Common Stock |
2022-11-01 | Gross Paul Edward | Buy | 5 623 | Common Stock |
2022-11-02 | Gross Paul Edward | Sell | 2 135 | Common Stock |
2022-11-02 | Gross Paul Edward | Sell | 2 595 | Common Stock |
2022-11-01 | Gross Paul Edward | Sell | 4 625 | Restricted Stock Units |
INSIDER POWER |
---|
-6.27 |
Last 100 transactions |
Buy: 146 624 | Sell: 133 052 |
ボリューム 相関
Clovis Oncology, Inc. 相関
10 最も正の相関 | |
---|---|
RXRAW | 0.853 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Clovis Oncology, Inc. 相関 - 通貨/商品
Clovis Oncology, Inc. 財務諸表
Annual | 2021 |
収益: | $148.76M |
総利益: | $109.93M (73.90 %) |
EPS: | $-2.18 |
FY | 2021 |
収益: | $148.76M |
総利益: | $109.93M (73.90 %) |
EPS: | $-2.18 |
FY | 2020 |
収益: | $164.52M |
総利益: | $123.22M (74.89 %) |
EPS: | $-4.38 |
FY | 2019 |
収益: | $143.01M |
総利益: | $108.32M (75.75 %) |
EPS: | $-7.43 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Clovis Oncology, Inc.
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3);and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. In addition, the company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. Clovis Oncology, Inc. was incorporated in 2009 and is headquartered in Boulder, Colorado. On December 11, 2022, Clovis Oncology, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。